MTCR 0.55 Metacrine, Inc.
| Range: | 0.303-0.5905 | Vol Avg: | 52473 | Last Div: | 0.58 | Changes: | 0.49 |
| Beta: | -0.74 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 16 2020 | Empoloyees: | 10 | ||
| CUSIP: | 59101E103 | CIK: | 0001634379 | ISIN: | US59101E1038 | Country: | US |
| CEO: | Mr. David M. Maggio | Website: | https://www.metacrine.com | ||||
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow